Multiple Myeloma
EU Focus Meeting 2026
📍 Lisbon, Portugal
🗓️ October 30 - 31, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Multiple Myeloma Focus Meeting 2026, to be held at on October 30 - 31, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Multiple Myeloma research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Multiple Myeloma EU Focus Meeting 2026:
Maria-Victoria Mateos, MD
University Hospital of Salamanca, Spain
Philippe Moreau, MD
The University Hospital of Nantes, France
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
freya.symons@md-education.com
Agenda & Faculty
October 30, 2026 | Day 1
Session I: Novel Diagnostic Platforms and Precursor Disease States
Moderated by:
Marivi Mateos, MD
09:00 AM
Replacing FISH with Sequencing Platforms
Jill Corre, MD
Institut Universitaire du Cancer de Toulouse, France
09:20 AM
Role of Mass Spectrometry in Diagnosis and Monitoring
Noemí Puig, MD
University Hospital of Salamanca, Spain
09:40 AM
The Immune Landscape in Precursor Disease and Multiple Myeloma
Bruno Paiva, MD
Universidad de Navarra, Pamplona, Spain
10:30 AM
Fellow/Junior Faculty CASE and Q&A
Alexis Talbot, MD
Greater Paris University Hospitals, Paris, France
Session II: Newly Diagnosed Multiple Myeloma
Moderated by:
Philippe Moreau, MD
11:05 PM
Quadruplets for ALL?
Aurore Perrot, MD
Université de Toulouse, France
11:25 PM
Defining Frailty and Treatment of Frail Patients
Sonja Zweegman, MD
Amsterdam UMC, Netherlands
11:45 PM
Tailoring the Maintenance Regimen and Duration
Elena Zamagni, MD
University of Bologna, Italy
12:35 PM
Fellow/Junior Faculty CASE and Q&A
TBD
TBD
Session III: High Risk Disease
Moderated by:
Katja Weisel, MD
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
02:25 PM
Defining High Risk Disease
Martin Kaiser, MD
Royal Marsden NHS Foundation Trust, London, UK
02:45 PM
Should High Risk Disease be Treated Differently?
Cyrille Touzeau, MD
The University Hospital of Nantes, France
03:05 PM
Clinical Trials Targeting High Risk Disease
Katja Weisel, MD
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
03:55 PM
Case Discussion and Q&A
TBD
TBD
Session IV: Relapse MM
Moderated by:
TBD
KOL TBD
KOL TBD
04:30 PM
Approaching Disease Relapse - Treatment Approaches Excluding Immunotherapies
Paula Rodríguez Otero, MD
Clínica Universidad de Navarra, Spain
04:50 PM
Belamaf: The Comeback Kid?
Evangelos Terpos, MD
University of Athens, Greece
05:10 PM
Targeted therapy in RR MM: BCL2i, MMSET, BRAF
Marc Raab, MD
Heidelberg Myeloma Center, Germany
06:00 PM
Fellow/Junior Faculty CASE and Q&A
TBD
TBD
October 31, 2026 | Day 2
Session V: Immunotherapies in MM
Moderated by:
Philippe Moreau, MD
The University Hospital of Nantes, France
09:00 AM
Use of Bispecifics in MM
Niels van de Donk, MD
Amsterdam UMC, Netherlands
09:20 AM
CAR-T Cells in MM
Hermann Einsele, MD
Würzburg University Hospital, Germany
09:40 AM
Novel Targets and Newer Approaches
Rakesh Popat, MD
University College London Hospitals NHS Foundation Trust, UK
10:30 AM
Fellow/Junior Faculty CASE and Q&A
TBD
TBD
Session VI: Other Plasma Cell Disorders
Moderated by:
TBD
KOL TBD
KOL TBD
11:05 AM
CAR-T Cells in MMAL Amyloidosis
Paolo Milani, MD
IRCCS Policlinico San Matteo, Pavia, Italy
11:25 AM
Waldenstroms
Ramón García Sanz, MD
University Hospital of Salamanca, Spain
12:15 PM
Fellow/Junior Faculty CASE and Q&A
TBD
TBD
Freya Symons
Project Manager
How long has Freya Symons been in the business?
Freya Symons has been with MD Education since 2025.
About Freya Symons
